Mesentech has developed novel chemistry that selectively delivers pharmaceuticals to a specific tissue. The advantage of our technology is that exposure to the active pharmaceutical occurs only in the targeted tissues, thereby eliminating toxicity to unrelated organs.Â
Our first product harnesses tissue-targeting technology to deliver prostaglandin, a potent hormone that triggers the body's own regenerative process, to renew and repair bone. It's safety profile would support its use not only in osteoporosis but also in certain pediatric osteoporosis diseases.Â
Â
Â
Latest News
09.04.21 | Bob Ward joins Mesentech's Board of Directors |
10.03.21 | New article "Design, Synthesis, Pharmacokinetics, and Biodistribution of a Series of Bone-Targeting EP4 Receptor Agonist Prodrugs for Treatment of Osteoporosis and Other Bone Conditions" |
26.02.21 | New article "Effects of treatment with a bone-targeted prostaglandin E2 receptor 4 agonist C3 (Mes-1007) in a mouse model of severe osteogenesis imperfecta" |
 | More |
Â
Mesentech has developed novel chemistry that selectively delivers pharmaceuticals to a specific tissue. The advantage of our technology is that exposure to the active pharmaceutical occurs only in the targeted tissues, thereby eliminating toxicity to unrelated organs.Â
Our first product harnesses tissue-targeting technology to deliver prostaglandin, a potent hormone that triggers the body's own regenerative process, to renew and repair bone. It's safety profile would support its use not only in osteoporosis but also in certain pediatric osteoporosis diseases.Â
Â
Â
Latest News
09.04.21 | Bob Ward joins Mesentech's Board of Directors |
10.03.21 | New article "Design, Synthesis, Pharmacokinetics, and Biodistribution of a Series of Bone-Targeting EP4 Receptor Agonist Prodrugs for Treatment of Osteoporosis and Other Bone Conditions" |
26.02.21 | New article "Effects of treatment with a bone-targeted prostaglandin E2 receptor 4 agonist C3 (Mes-1007) in a mouse model of severe osteogenesis imperfecta" |
 | More |
Â